David Geffen School of Medicine at UCLA-ko ikertzaileekin lankidetzan egindako argitalpenak (23)

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378

2022

  1. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  2. Central Role of the Antigen-Presentation and Interferon-γ Pathways in Resistance to Immune Checkpoint Blockade

    Annual Review of Cancer Biology, Vol. 6, pp. 85-102

  3. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

  4. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

    The Lancet Oncology, Vol. 23, Núm. 1, pp. 77-90

  5. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

2021

  1. Comparison of Multimodal Therapies and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features

    JAMA Network Open, Vol. 4, Núm. 7

  2. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer[Formula presented]

    European Urology, Vol. 80, Núm. 2, pp. 142-146

  3. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

    JAMA Network Open, Vol. 4, Núm. 12, pp. E2138550

  4. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9

2018

  1. Heterogeneity within the PF-EPN-B ependymoma subgroup

    Acta Neuropathologica, Vol. 136, Núm. 2, pp. 227-237

2016

  1. Immunodynamics: A cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

    Journal for ImmunoTherapy of Cancer, Vol. 4, Núm. 1

  2. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis

    Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2468-2477

2015

  1. Consensus nomenclature for CD8+ T cell phenotypes in cancer

    OncoImmunology, Vol. 4, Núm. 4

  2. Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014

    Journal of Translational Medicine, Vol. 13, Núm. 1

2014

  1. Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

    Journal of Translational Medicine, Vol. 12, Núm. 1

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine

  2. Identifying polyglutamine protein species in situ that best predict neurodegeneration

    Nature Chemical Biology, Vol. 7, Núm. 12, pp. 925-934

2004

  1. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

    Nature, Vol. 431, Núm. 7010, pp. 805-810